


What is Macula Risk PGx

Macula Risk PGx is a combined prognostic and pharmacogenetic DNA test designed to determine a patient's risk of progression to advanced Age-related Macular Degeneration (AMD) and aid in the selection of appropriate eye vitamin therapies based on his or her individual genetic risk profile.



Advanced AMD Prognosis

Macula Risk PGx predicts a patient's risk of progression to advanced AMD with vision loss within 2, 5 and 10 years.


Validated risk determinations of two large and independent populations show test sensitivity and specificity each greater than 80% and a 10-year predictive accuracy of 89.5%¹.

Genotype-Directed Eye Vitamin Therapy


The **Vita Risk™** pharmacogenetic result within the Macula Risk PGx test supports the selection of appropriate eye vitamin therapies for a patient based on their combined genotype at the CFH and ARMS2 loci. A pharmacogenetic analysis of AREDS concluded that **49% of patients** with moderate disease in at least one eye would derive greater benefit from a treatment regimen **other than** the AREDS formulation².

Genotype-directed therapy more than doubles the reduction in AMD progression rate compared to treatment with the AREDS formulation².

■ Placebo
■ AREDS Formulation
■ Genotype-Directed Therapy



Estimated probabilities of progression to Advanced AMD as a function of genotype, treatment group, and time (years):



- Placebo (No Treatment)
- Antioxidants Alone
- Zinc Alone
- Antioxidants + Zinc (AREDS Formulation)

Figure modified from Awh et al., CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology (In press).



Getting started is simple.
Sign up to become a Provider

Need Testing Supplies?
Contact us to place your order.

Contact Us:
1 (866) 964-5182
customerservice@macularisk.com